

Title Page

Perceptions and Attitudes Towards COVID-19 Vaccination Amongst Pregnant and Postpartum Individuals

Molly R. Siegel, MD^{1,2}, Mario I. Lumbreras-Marquez, MBBS³, MMSc, Kaitlyn James PhD^{1,2}, Brandon R. McBay⁴, Kathryn J. Gray, MD, PhD^{2,5}, Julianna Schantz-Dunn, MD^{2,5}, Khady Diouf, MD^{2,5*} and Ilona T. Goldfarb, MD, MPH^{1,2*}

¹ Department of Obstetrics, Gynecology, and Reproductive Biology, Massachusetts General Hospital, Boston, MA

² Harvard Medical School, Boston, MA

³ Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital, Boston, MA

⁴ Department of Social and Behavioral Sciences, Harvard T.H.Chan School of Public Health, Boston, MA

⁵ Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, MA

*Both Drs. Diouf and Goldfarb have contributed to this project to meet the role of senior author

Corresponding Author: Molly R. Siegel, MD Mailing address: 55 Fruit Street, Austen 4, Boston, MA 02114. Telephone: (617) 724-9408. Fax: (617) 724-3498. Email: mrsiegel@partners.org.

Word Count: Text is 2464 words and 10 pages. There are 2 figures and 1 table.

Conflicts of Interest: The authors report no conflicts of interest.

Financial Disclosures: Dr. Gray has consulted for Illumina Inc., Aetion, and BillionToOne outside the scope of the submitted work. No other financial disclosures are reported by the authors of this paper.

Abstract:

Introduction: This study aims to characterize attitudes towards COVID-19 vaccination and to evaluate factors associated with vaccine uptake amongst pregnant individuals.

Methods: An anonymous survey was distributed to a convenience sample of pregnant individuals receiving prenatal care at two large urban academic hospitals in a single healthcare network in Massachusetts. Individual demographic variables were included in the survey along with questions assessing attitudes towards COVID-19 and vaccination in pregnancy.

Results: Of 477 respondents, 233 (49.3%) had received or were scheduled to receive a COVID-19 vaccine. Age, White race, non-Hispanic/LatinX ethnicity, working from home, and typical receipt of the influenza vaccine were associated with COVID-19 vaccination. 276 respondents (58.4%) reported that their provider recommended the COVID-19 vaccine in pregnancy; these participants were more likely to have received a vaccine (OR 5.82, 95% confidence interval [CI] 3.68-9.26). Vaccinated individuals were less likely to be worried about the effects of the vaccine on themselves (OR 0.18, 95% CI 0.12-0.27) or their developing babies (OR 0.17, 95% CI 0.11-0.26). Unvaccinated individuals were less likely to report that it is easy to schedule a COVID-19 vaccine (OR 0.56, 95% CI 0.34-0.93), to travel to receive a vaccine (OR 0.19, 95% CI 0.10-0.36), and to miss work to receive a vaccine (OR 0.30, 95% CI 0.18-0.48).

Conclusions: Strategies are needed to improve patient education regarding vaccine side effects and safety in pregnancy and to change policy to make it feasible for pregnant patients to schedule and miss work without loss of pay to get vaccinated.

Key Points:

1. There were racial and ethnic disparities in COVID-19 vaccination.
2. Unvaccinated respondents were more likely to be concerned about vaccine effects for themselves or their growing babies.
3. Unvaccinated respondents cited work and scheduling-related barriers to vaccination, indicating areas for advocacy

Keywords: Pregnancy, vaccine hesitancy, racial disparities, COVID-19, vaccine barriers

1 Introduction:

2 Pregnant individuals are at increased risk for severe COVID-19, with higher rates of
3 hospitalization, intensive care unit (ICU) admission, and death compared to their non-pregnant
4 peers.¹⁻⁵ COVID-19 is also associated with increased rates of adverse pregnancy outcomes such
5 as pre-eclampsia, preterm birth, and cesarean delivery.⁶⁻¹⁰ Immunization with the messenger
6 RNA (mRNA) and the viral vector COVID-19 vaccines has been shown to significantly reduce
7 SARS-CoV-2 related morbidity and mortality, making immunizations essential to pandemic
8 control. Unfortunately, pregnant individuals were not included in the initial COVID-19 vaccine
9 trials, leading some providers to be reticent to recommend COVID-19 vaccination early in the
10 vaccine rollout.^{11,12} However, recent post-approval studies suggest that COVID-19 vaccination is
11 safe in pregnant and postpartum persons and effective in reducing maternal infections, morbidity,
12 and mortality.¹³⁻¹⁶

13

14 In light of the post-authorization data demonstrating safety in pregnancy, the increased spread of
15 new SARS-CoV-2 variants of concern, and the growing body of evidence surrounding the risks
16 of COVID-19 in pregnancy, the American College of Obstetrics and Gynecology (ACOG), the
17 Society for Maternal Fetal Medicine (SMFM), and the Centers for Disease Control and
18 Prevention (CDC) now recommend COVID-19 vaccination in pregnancy.¹⁷⁻¹⁹ Despite this
19 recommendation, pregnant persons continue to have lower vaccination rates than the general
20 population.²⁰ In the United States, COVID-19 vaccination in pregnant individuals remains lower
21 than average rates of influenza and Tdap immunization, indicating that there are individuals who
22 may typically accept vaccines who have not yet been vaccinated against COVID-19.²¹
23 Furthermore, globally observed racial and ethnic disparities in COVID-19 vaccination, infection,

24 morbidity, and mortality persist in pregnant individuals and parallel that of the general
25 population.^{20,22} Understanding factors associated with vaccine hesitancy is thus vital to improve
26 vaccination rates, curb infection-related morbidity and mortality, and reduce COVID-19 related
27 disparities.

28

29 Lack of inclusion of pregnant women in vaccine trials as well as lack of long-term safety data
30 have been posited as reasons for low vaccine uptake in pregnancy.²³⁻²⁵ However, factors
31 associated with COVID-19 vaccine acceptance in pregnancy remain understudied. In this study,
32 we surveyed pregnant and postpartum individuals in the outpatient setting to characterize
33 perceptions and attitudes towards COVID-19 vaccination and to evaluate factors associated with
34 vaccine uptake and vaccine hesitancy.

35

36

37 Methods:

38 *Participants*

39 Survey participants were from a cross-sectional convenience sample of pregnant and postpartum
40 individuals aged 18 or older receiving prenatal care at two large urban academic hospitals and
41 three affiliated community health centers in a single healthcare network in Massachusetts from
42 June to August 2021. Participants were approached by study staff during outpatient prenatal and
43 ultrasound visits and were offered participation. Consent to participate in the survey was implied
44 by voluntary participation in the anonymous survey. The study and survey instrument were
45 approved by the Mass General Brigham IRB (protocol # 2021P001086).

46

47 *Survey*

48 A paper-based anonymous survey was designed to accommodate quantitative analysis of
49 questions with nominal, ordinal, and interval level measurements. A copy of the survey is shown
50 in the Appendix. Individual demographics were included in the survey along with questions
51 assessing attitudes towards general vaccination, COVID-19 vaccination, and COVID-19 in
52 pregnancy. The study was offered to participants in English and Spanish.

53

54 *Data Analysis*

55 Data are presented as mean (standard deviation [SD]), median (interquartile range [IQR]), or
56 number (%). For quantitative variables, descriptive statistics are presented to illustrate the
57 distribution of the respondent demographics and survey responses. Associational odds ratios
58 (ORs) were calculated via univariable logistic regression. Parametric or nonparametric tests (chi-
59 square or Fisher's exact test) were used to analyze categorical variables, after evaluation for cell
60 size. Student's *t*-test or Wilcoxon rank-sum tests were used to analyze continuous variables. A
61 two-sided $P < 0.05$ was considered statistically significant with correction for multiple testing
62 where appropriate. Data were analyzed using Stata (IC 16.1, Stata Corp, TX).

63

64 Results

65 *Patient Demographics*

66 Between June-August 2021, 477 pregnant and postpartum individuals completed the survey out
67 of 684 distributed, a response rate of 69.7%. 4 individuals did not report their vaccination status
68 and were excluded from these analyses for a total of 473 responses in the final analyses: 453
69 were pregnant, and 19 postpartum with 1 respondent who did not report their pregnancy status.

70 Overall, 233 individuals (49.3%) had received or were scheduled to receive a COVID-19
71 vaccine. Participant demographics by vaccination status are shown in Table 1. Age, working
72 from home, and typical receipt of the influenza vaccine were associated with COVID-19
73 vaccination. Individuals who identified as Hispanic/LatinX were less likely to be vaccinated than
74 those who identified as non-Hispanic/Latinx (37.3% of Hispanic/LatinX vs 55.4% of non-
75 Hispanic/LatinX, $p=0.003$ after adjustment for multiple comparisons). Respondents who
76 identified as Black or African American were less likely than those who identified as White to be
77 vaccinated (18.3% of Black or African American vs 62.6% of White respondents, $p<0.001$).
78 Additionally, those who identified their race as Other or whose race was Unknown were less
79 likely than those who identified as White to be unvaccinated (32.4% vs 62.6%, $p<0.001$ for
80 Other vs White and 32.8% vs 62.6%, $p<0.001$ for Unknown vs White). There were no
81 differences in vaccination rates between pregnant and postpartum individuals (50.1% of pregnant
82 respondents vs 30.6% postpartum, $p=0.16$).

83
84 225 of the vaccinated respondents (96.5%) disclosed the type of vaccine they received: 214
85 (95.1%) had received one or both doses of an mRNA vaccine (either Pfizer or Moderna), 10
86 (4.4%) had received a J&J/Janssen viral vector vaccine, and 1 (0.4%) was unsure of their vaccine
87 type. Of unvaccinated individuals ($n=240$), 14 (5.8%) planned to receive a vaccine during
88 pregnancy. 276 respondents (58.4%) agreed or strongly agreed that their provider recommended
89 the COVID-19 vaccine in pregnancy; these participants were more likely to have received a
90 vaccine (OR 5.82, 95% confidence interval [CI] 3.68-9.26).

91

92 *SARS-CoV-2 Infection Attitudes*

93 Attitudes towards SARS-CoV2 infection between those who were unvaccinated and those who
94 were vaccinated are shown in Figure 1. Vaccinated individuals were more likely than
95 unvaccinated to agree or strongly agree that they feared COVID-19 during pregnancy, that if
96 they were infected they were at risk for getting very sick, and that they knew someone who was
97 hospitalized due to COVID-19. Those who were unvaccinated were more likely to agree or
98 strongly agree that at some point in the pregnancy they believed they had SARS-CoV-2 infection
99 and were more likely to have had a confirmed diagnosis of SARS-CoV-2 infection in pregnancy.
100 One person in the cohort had been hospitalized due to COVID-19; that individual was not
101 vaccinated.

102

103 *Factors associated with Vaccine Hesitancy*

104 Factors associated with vaccine hesitancy are shown in Figure 2. Unvaccinated individuals were
105 more likely to agree or strongly agree that the vaccine was rushed and that they were worried
106 about toxins in the vaccine. They were also more likely to agree or strongly agree that they were
107 worried about the side effects of the vaccine for themselves or their baby or that the vaccine
108 would cause them to contract COVID-19. Unvaccinated individuals were less likely to agree or
109 strongly agree that they trust vaccine developers and that people of their race and ethnicity were
110 included in vaccine trials. Vaccinated individuals were more likely to agree or strongly agree that
111 the vaccine would protect them or their baby from becoming infected.

112

113 *Barriers to Vaccination*

114 Unvaccinated individuals were less likely to agree or strongly agree that it is easy to schedule a
115 COVID-19 vaccine (OR 0.56, 95% CI 0.34-0.93), that it would be easy to travel to receive a

116 vaccine (OR 0.19, 95% CI 0.10-0.36), that it would be easy to miss work to receive a vaccine
117 (OR 0.30, 95% CI 0.18-0.48), and that it would be easy to miss time with family to receive a
118 vaccine (OR 0.27, 95% CI 0.16-0.43).

119

120 *Effect of ACOG and CDC Statements*

121 There were 35 respondents who completed the survey after the July 30, 2021 ACOG statement
122 recommending COVID-19 vaccination in pregnancy and 23 who completed after the August 11,
123 2021 CDC statement recommending COVID-19 vaccination in pregnancy. There were no
124 differences in self-reported vaccination rates in this cohort before and after the ACOG statement
125 ($p=0.98$) or before and after the CDC statement ($p=0.98$). There were no changes to the above
126 reported differences in baseline demographics, attitudes towards SARS-CoV2 infection, vaccine
127 hesitancy, or barriers to vaccination after excluding those who responded after the ACOG
128 statement (data not presented).

129

130 Discussion

131 In this cross-sectional study, only half of pregnant women reported receiving at least one dose of
132 a COVID-19 vaccine, and few of those who had not been vaccinated planned to receive a
133 vaccine during pregnancy. While this number is higher than the global and United States national
134 reported rates of COVID-19 vaccination in pregnancy, it is lower than the Massachusetts adult
135 vaccination rate of 63.6% at the time of this survey distribution and lower than this group's self-
136 reported acceptance of influenza vaccination (74.7%).^{20,26} These findings add to the growing
137 body of evidence pointing towards suboptimal COVID-19 vaccination rates in pregnant
138 individuals. Our findings are similar to the survey results by Sutton et al. in New York City,

139 which showed that pregnant respondents were less likely to accept vaccination compared with
140 non-pregnant female respondents.²⁵ Similarly, Turocy et al. performed a survey of patients
141 seeking fertility treatment and found that those who were planning pregnancy or currently
142 pregnant were less likely to accept vaccination than those who were not planning pregnancy.²⁷
143 This may be because there is more vaccine hesitancy amongst pregnant individuals than non-
144 pregnant individuals for vaccination in general. For example, prior studies have demonstrated
145 suboptimal rates of influenza vaccination and Tdap vaccination in pregnancy, citing concerns
146 about vaccine safety, lack of counseling, and disbelief in severity of disease.^{21,28}

147

148 Our study identified several factors associated with receipt of COVID-19 vaccination. Those
149 who worked remotely were more likely to be vaccinated, whereas those who were not currently
150 working were less likely to be vaccinated. Those who were vaccinated against COVID-19 were
151 more likely to report that they typically receive the influenza vaccine, indicating that in general
152 they are more accepting of vaccination.

153

154 Importantly, there were racial and ethnic disparities in COVID-19 vaccination rates in this
155 population. Only 42% of those who identified as Hispanic/LatinX and 19% of those who
156 identified as Black and 32.4% of those who identified as Other reported receiving a vaccine, as
157 compared with 55% of those who identified as non-Hispanic/LatinX and 64% of those who
158 identified as White. Furthermore, those who had not received a vaccine were less likely to agree
159 that people of their race and ethnicity were included in vaccine trials. These data mirror national
160 trends in vaccination rates in non-pregnant individuals.⁴ These findings highlight a need for
161 broader inclusion of individuals of non-White race in vaccine trials and vaccination campaigns to

162 ensure equitable access to and trust in vaccination. As has been previously argued, the burden of
163 these disparities in vaccination rates should not fall on the patients but rather on the health
164 systems and providers that initiate and preserve inequity and mistrust.²⁹

165

166 Survey respondents who had not received a COVID-19 vaccine were less likely to agree that
167 they trusted vaccine developers and were more likely to feel that the vaccine was rushed. They
168 were more worried about vaccine side effects and the effects of the vaccine on their developing
169 fetus. These findings support the work by Skjefte et al., an international survey distributed
170 electronically that found that pregnant individuals were worried about fetal effects, lack of safety
171 data in pregnancy, and rushed development of vaccines.²⁴ Our study builds on these data by
172 comparing concerns between pregnant persons who are and are not vaccinated. Unvaccinated
173 individuals were more likely to have been infected by SARS-CoV-2 during pregnancy and less
174 likely to be fearful of COVID-19 or to believe that if they contracted SARS-CoV-2 they were at
175 risk of becoming very sick. These findings provide areas for improved patient counseling
176 surrounding the risks of SARS-CoV-2 infection in pregnancy and the safety of vaccination, as
177 post-approval studies have not shown more severe side effects in pregnant individuals or
178 detrimental effects of the vaccine on pregnancies or fetal and neonatal outcomes.^{30,31} They also
179 highlight the importance of ongoing long-term follow-up studies to evaluate the health of
180 children exposed to vaccination during pregnancy to provide families with long-term safety data.

181

182 Respondents who were not vaccinated against COVID-19 identified several barriers to
183 vaccination, including concerns about missing work or time with family as well as difficulty
184 scheduling a vaccine. These are thus areas for advocacy to diminish the effects of these logistical

185 barriers: vaccine recovery days could be protected and paid time off so that patients do not worry
186 about missing time from work, vaccines can be mandated at workplaces to normalize vaccination
187 and missing work to attend vaccine appointments, and they should be made available at
188 expanded hours and at places that are frequently visited such as at workplaces and grocery
189 stores.³²⁻³⁴ Reducing some of these barriers to vaccination may lead to higher vaccination rates
190 and reduced inequities in immunization status observed in our study and previous analyses.

191

192 While most respondents in this study had discussed COVID-19 vaccination with their obstetric
193 providers, just over half reported that their provider recommended COVID-19 vaccination in
194 pregnancy. Given that provider confidence and recommendation of vaccination has consistently
195 been shown to be a strong predictor of patient vaccination rates particularly in a pregnant
196 population, it is imperative that providers feel comfortable engaging in conversations with
197 patients surrounding immunization.^{35,36} Now that the CDC and ACOG both recommend COVID-
198 19 vaccination in pregnancy, providers should routinely discuss and recommend these vaccines
199 to their patients with attention to addressing myths, misconceptions, and logistical barriers.
200 National and institution-specific counseling guides may assist in the implementation of these
201 recommendations.

202

203 Strengths of this analysis include its large sample size and high response rate as well as diverse
204 patient population. It is novel in its assessment of barriers to vaccination and comparisons of
205 vaccination concerns amongst pregnant individuals who were and were not vaccinated. It was
206 also conducted when all patients were eligible to receive vaccination, thus eliminating any
207 hesitation due to lack of eligibility. Limitations include that it was conducted when the CDC and

208 ACOG guidance was to offer, but not necessarily recommend, vaccination to pregnant patients.
209 Acceptance of vaccination may be higher now that these organizations have provided stronger
210 guidance regarding vaccination in pregnancy. Furthermore, the survey did not ask participants to
211 differentiate their responses based on receipt or consideration of mRNA or viral vector vaccine,
212 and it is possible that participants may have had different concerns depending on vaccine type.
213

214 Conclusions

215 Given the known increased risks of SARS-CoV-2 infection in pregnancy and the ongoing high
216 case rates globally, vaccination of pregnant individuals is paramount to halting disease
217 transmission and reducing barriers in SARS-CoV-2-related morbidity and mortality. An
218 understanding of the factors associated with reduced vaccine uptake and the socioeconomic
219 barriers to vaccination enables action to improve patient counseling and eliminate disparities in
220 vaccination rates amongst pregnant individuals.

Acknowledgements

Dr. Gray has consulted for Illumina Inc., Aetion, and BillionToOne outside the scope of the submitted work. No other financial disclosures are reported by the authors of this paper.

References

1. Ellington S, Strid P, Tong VT, et al. Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-June 7, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69(25):769-775. DOI: 10.15585/mmwr.mm6925a1.
2. Zambrano LD, Ellington S, Strid P, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69(44):1641-1647. DOI: 10.15585/mmwr.mm6944e3.
3. Yap M, Debenham L, Kew T, et al. Clinical manifestations, prevalence, risk factors, outcomes, transmission, diagnosis and treatment of COVID-19 in pregnancy and postpartum: a living systematic review protocol. *BMJ Open* 2020;10(12):e041868. DOI: 10.1136/bmjopen-2020-041868.
4. Prevention CfDCa. COVID Data Tracker. (<https://covid.cdc.gov/covid-data-tracker/#pregnant-population>).
5. Woodworth KR, Olsen EO, Neelam V, et al. Birth and Infant Outcomes Following Laboratory-Confirmed SARS-CoV-2 Infection in Pregnancy - SET-NET, 16 Jurisdictions, March 29-October 14, 2020. *MMWR Morb Mortal Wkly Rep* 2020;69(44):1635-1640. DOI: 10.15585/mmwr.mm6944e2.
6. Rajewska A, Mikolajek-Bedner W, Lebdowicz-Knul J, Sokolowska M, Kwiatkowski S, Torbe A. COVID-19 and pregnancy - where are we now? A review. *J Perinat Med* 2020;48(5):428-434. DOI: 10.1515/jpm-2020-0132.

7. Wei SQ, Bilodeau-Bertrand M, Liu S, Auger N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. *CMAJ* 2021;193(16):E540-E548. DOI: 10.1503/cmaj.202604.
8. Narang K, Enninga EAL, Gunaratne M, et al. SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review. *Mayo Clin Proc* 2020;95(8):1750-1765. DOI: 10.1016/j.mayocp.2020.05.011.
9. Di Mascio D, Sen C, Saccone G, et al. Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): a secondary analysis of the WAPM study on COVID-19. *J Perinat Med* 2020;48(9):950-958. DOI: 10.1515/jpm-2020-0355.
10. Di Mascio D, Khalil A, Saccone G, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM* 2020;2(2):100107. DOI: 10.1016/j.ajogmf.2020.100107.
11. Beigi RH, Krubiner C, Jamieson DJ, et al. The need for inclusion of pregnant women in COVID-19 vaccine trials. *Vaccine* 2021;39(6):868-870. DOI: 10.1016/j.vaccine.2020.12.074.
12. Maykin MM, Heuser C, Feltovich H. Pregnant people deserve the protection offered by SARS-CoV-2 vaccines. *Vaccine* 2021;39(2):171-172. (In eng). DOI: 10.1016/j.vaccine.2020.12.007.
13. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. *N Engl J Med* 2021;384(24):2273-2282. DOI: 10.1056/NEJMoa2104983.

14. Zauche LH, Wallace B, Smoots AN, et al. Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21. Res Sq 2021. DOI: 10.21203/rs.3.rs-798175/v1.
15. Goldshtein I, Nevo D, Steinberg DM, et al. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women. JAMA 2021. DOI: 10.1001/jama.2021.11035.
16. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol 2021. DOI: 10.1016/j.ajog.2021.03.023.
17. Statistics CfDC-NCfH. COVID-19 Vaccines While Pregnant or Breastfeeding. (<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html>).
18. Force SC-T. SMFM: Provider Considerations for Engaging in COVID-10 Vaccine Counseling with Pregnant and Lactating Patients. (https://s3.amazonaws.com/cdn.smfm.org/media/3070/Provider_Considerations_for_Engaging_in_COVID_Vaccination_Considerations_8-13-21_%28final%29_.pdf).
19. ACOG Immunization ID, and Public Health Preparedness Expert Work Group. COVID-19 Vaccination Considerations for Obstetric-Gynecologic Care. ACOG.org: ACOG, July 30, 2021 2021. (<https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care>).

20. Razzaghi H, Meghani M, Pingali C, et al. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021. *MMWR Morb Mortal Wkly Rep* 2021;70(24):895-899. DOI: 10.15585/mmwr.mm7024e2.
21. Razzaghi H KK, Black CL, et al. Influenza and Tdap Vaccination Coverage Among Pregnant Women — United States, April 2020.
22. Allotey J, Stallings E, Bonet M, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. *BMJ* 2020;370:m3320. DOI: 10.1136/bmj.m3320.
23. Goncu Ayhan S, Oluklu D, Atalay A, et al. COVID-19 vaccine acceptance in pregnant women. *Int J Gynaecol Obstet* 2021;154(2):291-296. DOI: 10.1002/ijgo.13713.
24. Skjefte M, Ngirbabul M, Akeju O, et al. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries. *Eur J Epidemiol* 2021;36(2):197-211. DOI: 10.1007/s10654-021-00728-6.
25. Sutton D, D'Alton M, Zhang Y, et al. COVID-19 vaccine acceptance among pregnant, breastfeeding, and nonpregnant reproductive-aged women. *Am J Obstet Gynecol MFM* 2021;3(5):100403. DOI: 10.1016/j.ajogmf.2021.100403.
26. Mass.gov. Massachusetts COVID-19 Vaccination Data and Updates (<https://www.mass.gov/info-details/massachusetts-covid-19-vaccination-data-and-updates#daily-covid-19-vaccine-report>).
27. Turocy J RA, Reshef E, D'Alton M, Forman E, Williams Z. A Survey of Fertility Patients' Attitudes Towards the COVID-19 Vaccine. *Fertility & Sterility* 2021

- <https://www.fertstertdialog.com/posts/a-survey-of-fertility-patients-attitudes-towards-the-covid-19-vaccine>).
28. Van Buynder PG, Van Buynder JL, Menton L, Thompson G, Sun J. Antigen specific vaccine hesitancy in pregnancy. *Vaccine* 2019;37(21):2814-2820. (In eng). DOI: 10.1016/j.vaccine.2019.04.021.
 29. Corbie-Smith G. Vaccine Hesitancy is a Scapegoat for Structural Racism. *Jama Health Forum* 2021 (<https://jamanetwork.com/channels/health-forum/fullarticle/2778073>).
 30. Garg I, Shekhar R, Sheikh AB, Pal S. COVID-19 Vaccine in Pregnant and Lactating Women: A Review of Existing Evidence and Practice Guidelines. *Infect Dis Rep* 2021;13(3):685-699. (In eng). DOI: 10.3390/idr13030064.
 31. Stafford IA, Parchem JG, Sibai BM. The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations. *Am J Obstet Gynecol* 2021;224(5):484-495. (In eng). DOI: 10.1016/j.ajog.2021.01.022.
 32. Coley KC, Gessler C, McGivney M, Richardson R, DeJames J, Berenbrok LA. Increasing adult vaccinations at a regional supermarket chain pharmacy: A multi-site demonstration project. *Vaccine* 2020;38(24):4044-4049. (In eng). DOI: 10.1016/j.vaccine.2020.02.040.
 33. Zhai Y, Santibanez TA, Kahn KE, Black CL, de Perio MA. Paid sick leave benefits, influenza vaccination, and taking sick days due to influenza-like illness among U.S. workers. *Vaccine* 2018;36(48):7316-7323. (In eng). DOI: 10.1016/j.vaccine.2018.10.039.
 34. Gessler CA, Richardson RM, Hall DL, Coley KC. Operationalizing Pandemic Vaccinations at a Regional Supermarket Chain Pharmacy. *Disaster Med Public Health Prep* 2021:1-6. (In eng). DOI: 10.1017/dmp.2021.43.

35. Paterson P, Meurice F, Stanberry LR, Glismann S, Rosenthal SL, Larson HJ. Vaccine hesitancy and healthcare providers. *Vaccine* 2016;34(52):6700-6706. DOI: 10.1016/j.vaccine.2016.10.042.
36. Wilson RJ, Paterson P, Jarrett C, Larson HJ. Understanding factors influencing vaccination acceptance during pregnancy globally: A literature review. *Vaccine* 2015;33(47):6420-9. DOI: 10.1016/j.vaccine.2015.08.046.

Figure 1: Attitudes Towards SARS-CoV2

Caption: *OR is relative to unvaccinated

Figure 2: Factors Associated with Vaccine Hesitancy

Caption: *OR is relative to unvaccinated

Table 1: Demographic Characteristics by Vaccination Status

	Vaccinated (n=233)	Unvaccinated (n=240)	P-value
Age, mean y (SD)	33.0 (4.5)	31.4 (5.6)	<0.005
Ethnicity, n (%)			0.002
Non-Hispanic/Latinx (n=285)	158 (67.8%)	127 (52.9%)	
Hispanic/Latinx (n=134)	50 (21.5%)	84 (35.0%)	
Unknown (n=54)	25 (10.7%)	29 (12.1%)	
Race, n (%)			<0.005
American Indian or Alaska Native (n=3, 0.63%)	0 (0%)	3 (1.3%)	
Asian (n=36, 7.6%)	17 (7.3%)	19 (7.9%)	
Black or African American (n=60, 12.7%)	11 (4.7%)	49 (20.4%)	
Native Hawaiian or Pacific Islander (n=1, 0.2%)	1 (0.4%)	0 (0%)	
White (n=275, 58.1%)	172 (73.8%)	103 (42.9%)	
Other (n=37, 7.8%)	12 (5.2%)	25 (10.4%)	
Unknown (n=61, 12.9%)	20 (8.6%)	41 (17.1%)	

Number of People in Household, mean (SD)	2.96 (1.3)	3.20 (1.5)	0.07
Work Location n (%)			<0.005
Working remotely (n=139)	87 (37.3%)	52 (21.7%)	
Working in person (n=145)	67 (28.8%)	78 (32.5%)	
Working both remotely and in person (n=68)	40 (17.2%)	28 (11.7%)	
Not currently working (n=115)	38 (16.3%)	77 (32.1%)	
Unknown (n=6)	1 (.43%)	5 (2.1%)	
Any medical comorbidities, n (%) *	50 (21.5%)	47 (19.6%)	0.66
Typically receive influenza vaccination, n (%)	201 (86.2%)	149 (62.1%)	<0.005

*Medical comorbidities were defined as self-report of cancer, renal disease, asthma, obesity, heart disease, hypertension, immune compromise, diabetes, sickle cell disease

Unvaccinated Vaccinated

Odds Ratio
with 95% CI

Factors associated with vaccine hesitancy

Factors associated with vaccine hesitancy	Unvaccinated	Vaccinated		Odds Ratio with 95% CI
Feel the vaccine was rushed	92	22		0.16 [0.10, 0.27]
Trust vaccine developers	80	174		6.52 [4.30, 9.91]
Believe people of their race and ethnicity were included in vaccine trials	92	149		2.65 [1.79, 3.92]
Worried about the side effects of the vaccine for themselves	159	64		0.18 [0.12, 0.27]
Worried about the side effects of the vaccine for their baby	175	77		0.17 [0.11, 0.25]
Believe the vaccine will cause them to contract COVID-19	22	5		0.21 [0.08, 0.56]
Worried about toxins in the vaccine	72	21		0.22 [0.13, 0.38]
Believe the vaccine will protect them from getting COVID-19	80	189		10.75 [6.73, 17.17]
Believe the vaccine will protect their baby from getting COVID-19	62	155		6.36 [4.16, 9.73]

1/8 1/2 2 8

Unvaccinated Vaccinated

Odds Ratio
with 95% CI

Attitudes towards SARS-COV-2

Attitudes towards SARS-COV-2	Unvaccinated	Vaccinated	Odds Ratio with 95% CI
Expressed fear of COVID-19 during pregnancy	129	179	2.45 [1.66, 3.62]
Believed that they were at risk for getting very sick if infected	104	139	1.90 [1.30, 2.78]
Diagnosed with COVID-19 prior to pregnancy	19	15	0.78 [0.39, 1.58]
Believed they had COVID-19 during pregnancy	34	19	0.52 [0.29, 0.95]
Diagnosed with COVID-19 during pregnancy	21	6	0.27 [0.11, 0.69]
Household member diagnosed with COVID-19	43	30	0.67 [0.41, 1.12]
Knew someone hospitalized with COVID-19	58	77	1.52 [1.02, 2.28]
Knew someone who died due to COVID-19	48	65	1.52 [0.99, 2.32]

1/8 1/4 1/2 1 2